A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped The positive results from IMpower010 demonstrated benefit by adding atezolizumab as adjuvant therapy in early stage NSCLC. These results raised ethical concerns of enrolling pts to best supportive care over checkpoint inhibition in this setting.

Conditions

Carcinoma, Non-Small Cell Lung

Interventions

DRUG: Atezolizumab
DRUG: Placebo
DRUG: Carboplatin
DRUG: Cisplatin
DRUG: Pemetrexed
DRUG: Gemcitabine
DRUG: Paclitaxel

Sponsor

Hoffmann-La Roche